Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 8/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196519 | 0.86 | GPR52 (0.47) | GPR52PRKDCS1PR4S1PR5 | |
| SCHEMBL3215801 | 0.84 | GPR52 (0.45) | GPR52PRKDCPIK3CA | |
| SCHEMBL3218822 | 0.83 | GPR52 (0.67) | GPR52 | |
| SCHEMBL1848119 | 0.81 | GPR52 (0.71) | GPR52S1PR4S1PR5 | |
| SCHEMBL3213279 | 0.80 | GPR52 (0.51) | GPR52PRKDCS1PR4S1PR5PIK3CA | |
| SCHEMBL1850789 | 0.80 | GPR52 (0.53) | GPR52PRKDCS1PR4S1PR5 | |
| SCHEMBL3204381 | 0.79 | GPR52 (0.49) | GPR52PRKDCS1PR4S1PR5PIK3CA | |
| SCHEMBL1849612 | 0.79 | GPR52 (0.48) | GPR52PRKDCS1PR4S1PR5 | |
| SCHEMBL3196491 | 0.79 | GPR52 (0.52) | GPR52S1PR4S1PR5 | |
| SCHEMBL1849195 | 0.79 | GPR52 (0.51) | GPR52S1PR4S1PR5PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | GPR52 1/4885PRKDC 4721/4885S1PR4 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.